activity
20052026
most citedElongation/Compaction of Giant DNA Caused by Depletion Interaction with a Flexible Polymer

36 citations · 38 across the 11 of their papers we have counts for

collaborators
Showing stat.MEShow all

8 papers · 1 filter

stat.ME2026

Likelihood-Ratio E-Value Monitoring for Benchmark-Based Decisions in Early-Phase Oncology Trials

Masahiro Kojima

Early-phase oncology trials often require protocol-ready interim rules for deciding whether an experimental regimen shows sufficient activity relative to prespecified clinical benc…

stat.ME2023

Dynamic Borrowing Method for Historical Information Using a Frequentist Approach for Hybrid Control Design

Masahiro Kojima

Information borrowing from historical data is gaining attention in clinical trials of rare and pediatric diseases, where statistical power may be insufficient for confirmation of e…

stat.ME2023

Adaptive Cohort Size Determination Method for Bayesian Optimal Interval Phase I/II Design to Shorten Clinical Trial Duration

Masahiro Kojima

Recently, the strategy for dose optimization in oncology has shifted to conduct Phase 2 randomized controlled trials with multiple doses. Optimal biologic dose selection from Phase…

stat.ME2022

Variable Selection using Inverse Survival Probability Weighting

Masahiro Kojima

In this paper, we propose two variable selection methods for adjusting the censoring information for survival times, such as the restricted mean survival time. To adjust for the in…

stat.ME2022

Comparison of Baseline Covariate Adjustment Methods for Restricted Mean Survival Time

Keisuke Hanada, Junji Moriya, Masahiro Kojima

The restricted mean survival time is a clinically easy-to-interpret measure that does not require any assumption of proportional hazards. We focus on two ways to directly model the…

stat.ME2022

Data-Dependent Early Completion of Dose Finding Trials for Drug-Combination

Masahiro Kojima

We propose a data-dependent early completion of dose finding trials for drug-combination. The early completion is determined when a beta-binomial probability for dose retainment wi…

stat.ME2021

Adaptive design for identifying maximum tolerated dose early to accelerate dose-finding trial

Masahiro Kojima

Purpose: The early identification of maximum tolerated dose (MTD) in phase I trial leads to faster progression to a phase II trial or an expansion cohort to confirm efficacy. Metho…

stat.ME2021

Adaptive Contrast Test for Dose-Response Studies and Modeling

Masahiro Kojima

We propose a powerful adaptive contrast test with ordinal constraint contrast coefficients determined by observed responses. The adaptive contrast test can perform using easily cal…